Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5601_Библиотеки_им_академика_М_И_Перельмана
.pdf
Lipid-Lowering Agents Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 159
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[11] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and
Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]
[12] Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on Heart Failure-Related
Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular
Disease: Results of the VERTIS CV Trial. Circulation 2020; 142(23): 2205-15.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050255] [PMID: 33026243]
[13] Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart
Failure. N Engl J Med 2020; 383(15): 1413-24.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]
[14] Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients
with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2020; 1-11.
[PMID: 33200892]
[15] Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with
Diabetes and Chronic Kidney Disease. N Engl J Med 2020; 1-11.
[PMID: 33200891]
[16] Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with
type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
[http://dx.doi.org/10.1056/NEJMoa1307684] [PMID: 23992601]
[17] White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute
coronary syndrome in patients with type 2 diabetes. Austrian J Clin Endocrinol Metab 2014; 7(2): 77.
[18] Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type
2 Diabetes. N Engl J Med 2015; 373(3): 232-42.
[http://dx.doi.org/10.1056/NEJMoa1501352] [PMID: 26052984]
[19] Sheu WHH, Gantz I, Chen M, et al. Safety and efficacy of omarigliptin (MK-3102), a novel Once-
Weekly DPP-4 Inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care 2015; 38(11):
2106-14.
[http://dx.doi.org/10.2337/dc15-0109] [PMID: 26310692]
[20] Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and
albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D
trial. Diabetes Obes Metab 2017; 19(11): 1610-9.
[http://dx.doi.org/10.1111/dom.13041] [PMID: 28636754]
[21] Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major
Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The
CARMELINA Randomized Clinical Trial. JAMA 2019; 321(1): 69-79.
[http://dx.doi.org/10.1001/jama.2018.18269] [PMID: 30418475]
[22] Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse
Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical
Trial. JAMA 2019; 322(12): 1155-66.
[http://dx.doi.org/10.1001/jama.2019.13772] [PMID: 31536101]
[23] Muskiet MHA, Tonneijck L, Smits MM, et al. Effects of DPP-4 inhibitor linagliptin versus
sulfonylurea glimepiride as add-on to metformin on renal physiology in overweight patients with type
2 diabetes (Renalis): A randomized, double-blind trial. Diabetes Care 2020; 43(11): 2889-93.
[http://dx.doi.org/10.2337/dc20-0902] [PMID: 32900785]
[24] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute
Coronary Syndrome. N Engl J Med 2015; 373(23): 2247-57.
[http://dx.doi.org/10.1056/NEJMoa1509225] [PMID: 26630143]
160 Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 Abdelfattah et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[25] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2
Diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[26] Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type
2 Diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141] [PMID: 27633186]
[27] Rosenstock J, Buse JB, Azeem R, et al. Efficacy and safety of ITCA 650, a novel drug-Device GLP-1
receptor agonist, in type 2 diabetes uncontrolled with oral antidiabetes drugs: The FREEDOM-1 trial.
Diabetes Care 2018; 41(2): 333-40.
[http://dx.doi.org/10.2337/dc17-1306] [PMID: 29242349]
[28] Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients
with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised
placebo-controlled trial. Lancet 2018; 392(10157): 1519-29.
[PMID: 30291013]
[29] Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular
Outcomes in Type 2 Diabetes. N Engl J Med 2017; 377(13): 1228-39.
[http://dx.doi.org/10.1056/NEJMoa1612917] [PMID: 28910237]
[30] Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2
diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193):
121-30.
[http://dx.doi.org/10.1016/S0140-6736(19)31149-3] [PMID: 31189511]
[31] Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in
Patients with Type 2 Diabetes. N Engl J Med 2019; 381(9): 841-51.
[http://dx.doi.org/10.1056/NEJMoa1901118] [PMID: 31185157]
[32] Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in
dysglycemia. N Engl J Med 2012; 367(4): 319-28.
[http://dx.doi.org/10.1056/NEJMoa1203858] [PMID: 22686416]
[33] Marso SP, McGuire DK, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2
Diabetes. N Engl J Med 2017; 377(8): 723-32.
[http://dx.doi.org/10.1056/NEJMoa1615692] [PMID: 28605603]
[34] Philis-Tsimikas A, Stratton I, Nørgård Troelsen L, Anker Bak B, Leiter LA. Efficacy and Safety of
Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes:
Trial Protocol Amendment (NCT03078478). J Diabetes Sci Technol 2019; 13(3):
498-506.http://journals.sagepub.com/doi/10.1177/1932296819841585
[http://dx.doi.org/10.1177/1932296819841585] [PMID: 30974986]
[35] Meneghini L, Blonde L, Gill J, et al. Insulin glargine 300 U/mL versus first-generation basal insulin
analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a
prospective, randomized, pragmatic real-life clinical trial. Diabetes Obes Metab 2020; 22(11): 1995-
2003.
[http://dx.doi.org/10.1111/dom.14116] [PMID: 32538550]
[36] Eldor Roy, Fleming GA, Neutel J, Homer KE, Kidron M, Rosenstock J. 105-LB: Evening Oral Insulin
(ORMD-0801) Glycemic Effects in Uncontrolled T2DM Patients. Diabetes 2020; 69 (Supplement 1):
105. http://diabetes.diabetesjournals.org/content/69/Supplement_1/105-LB
[37] Rosenstock J, Bajaj HS, Janež A, et al. Once-Weekly Insulin for Type 2 Diabetes without Previous
Insulin Treatment. N Engl J Med 2020; 383(22): 2107-16.
[http://dx.doi.org/10.1056/NEJMoa2022474] [PMID: 32960514]
[38] Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes
outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised,
Lipid-Lowering Agents Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 161
double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5(11): 877-86.
[PMID: 28917545]
[39] Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in
oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label
trial. Lancet 2009; 373(9681): 2125-35.
[http://dx.doi.org/10.1016/S0140-6736(09)60953-3] [PMID: 19501900]
[40] Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density
lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;
308(23): 2497-506.
[http://dx.doi.org/10.1001/jama.2012.25790] [PMID: 23128163]
[41] Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous
familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled
trial. Lancet 2015; 385(9965): 331-40.
[http://dx.doi.org/10.1016/S0140-6736(14)61399-4] [PMID: 25282519]
[42] Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in
patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of
evolocumab. J Am Coll Cardiol 2014; 63(23): 2541-8.
[http://dx.doi.org/10.1016/j.jacc.2014.03.019] [PMID: 24694531]
[43] Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in
hyperlipidemia. N Engl J Med 2014; 370(19): 1809-19.
[http://dx.doi.org/10.1056/NEJMoa1316222] [PMID: 24678979]
[44] Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the
MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014;
63(23): 2531-40.
[http://dx.doi.org/10.1016/j.jacc.2014.03.018] [PMID: 24691094]
[45] Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to
moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:
the LAPLACE-2 randomized clinical trial. JAMA 2014; 311(18): 1870-82.
[http://dx.doi.org/10.1001/jama.2014.4030] [PMID: 24825642]
[46] Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal
antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular
risk--primary results from the phase 2 YUKAWA study. Circ J 2014; 78(5): 1073-82.
[http://dx.doi.org/10.1253/circj.CJ-14-0130] [PMID: 24662398]
[47] Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular Efficacy and Safety of Bococizumab in
High-Risk Patients. N Engl J Med 2017; 376(16): 1527-39.
[http://dx.doi.org/10.1056/NEJMoa1701488] [PMID: 28304242]
[48] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with
Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[49] Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and
Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019; 73(4): 387-96.
[http://dx.doi.org/10.1016/j.jacc.2018.10.039] [PMID: 30428396]
[50] Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term Efficacy and Safety of Evolocumab in
Patients With Hypercholesterolemia. J Am Coll Cardiol 2019; 74(17): 2132-46.
[http://dx.doi.org/10.1016/j.jacc.2019.08.1024] [PMID: 31648705]
[51] Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with
dysglycemia. N Engl J Med 2012; 367(4): 309-18.
[http://dx.doi.org/10.1056/NEJMoa1203859] [PMID: 22686415]
162 Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 Abdelfattah et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[52] Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes
Mellitus. N Engl J Med 2018; 379(16): 1540-50.
[http://dx.doi.org/10.1056/NEJMoa1804989] [PMID: 30146932]
[53] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for
Hypertriglyceridemia. N Engl J Med 2019; 380(1): 11-22.
[http://dx.doi.org/10.1056/NEJMoa1812792] [PMID: 30415628]
[54] Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on
Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH
Randomized Clinical Trial. JAMA -. JAMA 2020; 44195(22): 1-13.
[http://dx.doi.org/10.1001/jama.2020.22258]
[55] Ni L, Yuan C, Chen G, Zhang C, Wu X, Zhang C, et al. SGLT2i: beyond the glucose-lowering effect.
Cardiovasc Diabetol 2020; 19(1): 98.
[http://dx.doi.org/10.1186/s12933-020-01071-y] [PMID: 32590982]
[56] Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;
21(1): 31-8.
[http://dx.doi.org/10.1002/dmrr.532] [PMID: 15624123]
[57] Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and
perspectives. Cardiovasc Diabetol 2019; 18(1): 20.
[http://dx.doi.org/10.1186/s12933-019-0828-y] [PMID: 30819210]
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
[58]
N Engl J Med :Internet. 2014/02/06. 2021 Nov 18;384(2):129–39. Available from:
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
[59] Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel
Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic
Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert
Consensus Decision Pathways. J Am Coll Cardiol 2018; 72(24): 3200-23.
[http://dx.doi.org/10.1016/j.jacc.2018.09.020] [PMID: 30497881]
[60] Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC Expert Consensus Decision Pathway for
Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With
Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert
Consensus Decision Pathways. J Am Coll Cardiol 2018; 71(2): 201-30.
[http://dx.doi.org/10.1016/j.jacc.2017.11.025] [PMID: 29277252]
[61] White JR. A Brief History of the Development of Diabetes Medications. Diabetes :Spectr [Internet].
2014 May;27(2):82 LP-- 86. Available from: http://spectrum.diabetesjournals.org/content/
27/2/82.abstract
[62] Brunton S. 2014.https://pubmed.ncbi.nlm.nih.gov/24499291
[63] Špinar J, Smahelová A. SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with
type 2 diabetes mellitus. Vnitr Lek 2013; 59(11): 1003-7.
[PMID: 24279445]
[64] Mann JFE, Nauck MA, Nissen SE, Pocock S, Ph D, Zinman B, et al. Liraglutide and cardiovascular
outcomes in type 2 diabetes. Drug Ther Bull 2016; 54(9): 101.
[65] Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, et al. 2017.
http://cmajopen.ca/lookup/doi/10.9778/cmajo.20160058
[66] Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes:
systematic review and meta-analysis of randomised and observational studies. BMJ 2016; 352:
i610.https://www.bmj.com/lookup/doi/10.1136/bmj.i610
[http://dx.doi.org/10.1136/bmj.i610] [PMID: 26888822]
[67] Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4
Lipid-Lowering Agents Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 163
inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110(6):
826-33.https://linkinghub.elsevier.com/retrieve/pii/S0002914912013446
[http://dx.doi.org/10.1016/j.amjcard.2012.04.061] [PMID: 22703861]
[68] Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular
risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15(2):
112-20.http://doi.wiley.com/10.1111/dom.12000
[http://dx.doi.org/10.1111/dom.12000] [PMID: 22925682]
[69] Alfayez OM, Almutairi AR, Aldosari A, Al Yami MS. Update on Cardiovascular Safety of Incretin-
Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular
Outcome Trials. Can J Diabetes 2019; 43(7): 538-545.e2.
[http://dx.doi.org/10.1016/j.jcjd.2019.04.003] [PMID: 31175007]
[70] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.
Diabetes Care 2020; 43 (Suppl. 1):
S98-S110.http://care.diabetesjournals.org/lookup/doi/10.2337/dc20-S009
[http://dx.doi.org/10.2337/dc20-S009] [PMID: 31862752]
[71] Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide
but not to liraglutide: Unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. Diabetes
Care 2019; 42(9): e141-2.
[http://dx.doi.org/10.2337/dc19-0720] [PMID: 31296642]
[72] Vecchio I, Tornali C, Bragazzi NL, Martini M. The discovery of insulin: An important milestone in
the history of medicine. Front Endocrinol (Lausanne) 2018; 9(October): 613.
[http://dx.doi.org/10.3389/fendo.2018.00613] [PMID: 30405529]
[73] White JR. A Brief History of the Development of Diabetes Medications. Diabetes Spectr 2005; 27(2):
82-6. Available from: http://spectrum.diabetesjournals.org/content/27/2/82.abstract.
[74] Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular
outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from
randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5(6): 431-7.
[http://dx.doi.org/10.1016/S2213-8587(17)30104-3] [PMID: 28365411]
[75] Reaven PD, Emanuele NV, Wiitala WL, et al. Intensive Glucose Control in Patients with Type 2
Diabetes - 15-Year Follow-up. N Engl J Med 2019; 380(23): 2215-24.
[http://dx.doi.org/10.1056/NEJMoa1806802] [PMID: 31167051]
[76] Kirkman MS, Mahmud H, Korytkowski MT. Intensive Blood Glucose Control and Vascular
Outcomes in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am 2018; 47(1):
81-96.
[http://dx.doi.org/10.1016/j.ecl.2017.10.002] [PMID: 29407058]
[77] Intensive Blood-Glucose Control with Sulfonylureas or Insulin Compared with Conventional
Treatment and Risk of Complications in Patients with Type 2 Diabetes. Endocrinologist 1999; 9(2):
149.
[http://dx.doi.org/10.1097/00019616-199903000-00016]
[78] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-
53.
[http://dx.doi.org/10.1016/S0140-6736(98)07019-6] [PMID: 9742976]
[79] Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med 2008; 358(24): 2545-59.
[http://dx.doi.org/10.1056/NEJMoa0802743] [PMID: 18539917]
[80] Philis-Tsimikas A, Klonoff DC, Khunti K, et al. Risk of hypoglycaemia with insulin degludec versus
insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head
CONCLUDE trial. Diabetologia 2020; 63(4): 698-710.
164 Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 Abdelfattah et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[http://dx.doi.org/10.1007/s00125-019-05080-9] [PMID: 31984443]
[81] Abdelfattah OM, Hassanein M, Saad AM, Abela G, Aldasouqi S. Fasting- Evoked En route
Hypoglycemia in Diabetes (FEEHD): From guidelines to clinical practice. Curr Diabetes Rev 2020;
16(9): 949-56.http://www.eurekaselect.com/178134/article
[http://dx.doi.org/10.2174/1573399816666200107103829] [PMID: 31914915]
[82] Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34
(SUPPL. 2).
[http://dx.doi.org/10.2337/dc11-s220]
[83] Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of
type 2 diabetes. Expert Opin Pharmacother 2019; 20(18): 2229-35.
[http://dx.doi.org/10.1080/14656566.2019.1672660] [PMID: 31593486]
[84] Krishnaswami A, Ravi-Kumar S, Lewis JM. Thiazolidinediones: a 2010 perspective. Perm J 2010;
14(3): 64-72.https://pubmed.ncbi.nlm.nih.gov/20844707
[http://dx.doi.org/10.7812/TPP/09-052] [PMID: 20844707]
[85] Vasudevan AR, Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin
sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004;
6(6): 850-63.
[http://dx.doi.org/10.1089/dia.2004.6.850] [PMID: 15684639]
[86] Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive
thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Curr Med Res Opin 2004; 20(2): 215-23.
[http://dx.doi.org/10.1185/030079903125002937] [PMID: 15006017]
[87] Khan S, Khan S, Imran M, Pillai KK, Akhtar M, Najmi AK. Effects of pioglitazone and vildagliptin
on coagulation cascade in diabetes mellitus--targeting thrombogenesis. Expert Opin Ther Targets
2013; 17(6): 627-39.
[PMID: 23356568]
[88] Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart
failure: a consensus statement from the American Heart Association and American Diabetes
Association. October 7, 2003. Circulation 2003; 108(23): 2941-8.
[http://dx.doi.org/10.1161/01.CIR.0000103683.99399.7E] [PMID: 14662691]
[89] Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in
patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In
macroVascular Events): a randomised controlled trial. Lancet 2005; 366(9493):
1279-89.https://linkinghub.elsevier.com/retrieve/pii/S0140673605675289
[http://dx.doi.org/10.1016/S0140-6736(05)67528-9] [PMID: 16214598]
[90] Hashim S, Gomes T, Juurlink D, Hellings C, Mamdani M. The rise and fall of the thiazolidinediones:
impact of clinical evidence publication and formulary change on the prescription incidence of
thiazolidinediones. J Popul Ther Clin Pharmacol = J la Ther des Popul la Pharmacol Clin 2013; 20(3):
e238-42.
[91] Elisabetta P, Ajinkya P, Jessica F, Mehdi N, Deborah W, Anouk D-L, et al. Abstract 11928:
Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor
Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety
(EMPRISE) Study. Circulation 2019; 140 (Suppl. 1): A11928-8. [Internet].
[http://dx.doi.org/10.1161/circ.140.suppl_1.11928]
[92] Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor
treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type
2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol 2019; 18(1):
138.https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0942-x
[http://dx.doi.org/10.1186/s12933-019-0942-x] [PMID: 31640705]
Lipid-Lowering Agents Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 165
[93] Endo A, Kuroda M. Citrinin, an inhibitor of cholesterol synthesis. J Antibiot (Tokyo) 1976; 29(8):
841-3.
[PMID: 791911]
[94] Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured
fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase
activity. Proc Natl Acad Sci USA 1974; 71(3): 788-92.
[http://dx.doi.org/10.1073/pnas.71.3.788] [PMID: 4362634]
[95] Nair P. Brown and Goldstein: the cholesterol chronicles. Proc Natl Acad Sci USA 2013; 110(37):
14829-32.
[http://dx.doi.org/10.1073/pnas.1315180110] [PMID: 23980185]
[96] Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, et al. Mevinolin: A highly potent
competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering
agent. Proc Natl Acad Sci USA 1980; 77(7 II): 3957–61.
[http://dx.doi.org/10.1073/pnas.77.7.3957]
[97] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
[PMID: 7968073]
[98] Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins
after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504.
[http://dx.doi.org/10.1056/NEJMoa040583] [PMID: 15007110]
[99] La Rosa JC, Conti CR. Intensive lipid lowering with atorvastatin in patients with stable coronary
disease. ACC Cardiosource Rev J 2006; 15(5): 97-9.
[100] Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient
ischemic attack. N Engl J Med 2006; 355(6): 549-59.
[http://dx.doi.org/10.1056/NEJMoa061894] [PMID: 16899775]
[101] Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in
men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas
Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615-22.
[http://dx.doi.org/10.1001/jama.279.20.1615] [PMID: 9613910]
[102] Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre
randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-96.
[http://dx.doi.org/10.1016/S0140-6736(04)16895-5] [PMID: 15325833]
[103] MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk
individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326):
7-22.https://linkinghub.elsevier.com/retrieve/pii/S0140673602093273
[http://dx.doi.org/10.1016/S0140-6736(02)09327-3] [PMID: 12114036]
[104] Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in
hypertensive patients who have average or lower-than-average cholesterol concentrations, in the
Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre
randomised controlled trial. Drugs 2004; 64 (Suppl. 2): 43-60.
[http://dx.doi.org/10.2165/00003495-200464002-00005] [PMID: 15765890]
[105] Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532
patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm
(ASCOT-LLA). Diabetes Care 2005; 28(5): 1151-7.
[http://dx.doi.org/10.2337/diacare.28.5.1151] [PMID: 15855581]
[106] Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and
women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-207.
166 Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 Abdelfattah et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[http://dx.doi.org/10.1056/NEJMoa0807646] [PMID: 18997196]
[107] Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing
hemodialysis. N Engl J Med 2005; 353(3): 238-48.
[http://dx.doi.org/10.1056/NEJMoa043545] [PMID: 16034009]
[108] Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients
undergoing hemodialysis. N Engl J Med 2009; 360(14): 1395-407.
[http://dx.doi.org/10.1056/NEJMoa0810177] [PMID: 19332456]
[109] Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N
Engl J Med 2007; 357(22): 2248-61.
[http://dx.doi.org/10.1056/NEJMoa0706201] [PMID: 17984166]
[110] Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart
failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;
372(9645): 1231-9.
[http://dx.doi.org/10.1016/S0140-6736(08)61240-4] [PMID: 18757089]
[111] Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL
cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;
376(9753): 1670-81.
[http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 21067804]
[112] Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin
therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised
trials. Lancet 2012; 380(9841): 581-90.
[http://dx.doi.org/10.1016/S0140-6736(12)60367-5] [PMID: 22607822]
[113] Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus
ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised
placebo-controlled trial. Lancet 2011; 377(9784): 2181-92.
[http://dx.doi.org/10.1016/S0140-6736(11)60739-3] [PMID: 21663949]
[114] Herrington WG, Emberson J, Mihaylova B, et al. Impact of renal function on the effects of LDL
cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28
randomised trials. Lancet Diabetes Endocrinol 2016; 4(10): 829-39.
[http://dx.doi.org/10.1016/S2213-8587(16)30156-5] [PMID: 27477773]
[115] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary
syndromes. N Engl J Med 2015; 372(25): 2387-97.https://www.scopus.com/inward/record.uri?eid=2s2.0-84931411520&doi=10.1056%2FNEJMoa1410489&partnerID=40&md5=e05871501a2f038a737
89cac14db7ec2
[http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]
[116] Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary
cardiovascular prevention among older adults: The ALLHAT-LLT randomized clinical trial. JAMA
Intern Med 2017; 177(7): 955-65.
[http://dx.doi.org/10.1001/jamainternmed.2017.1442] [PMID: 28531241]
[117] Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet 2003; 34(2): 154-6.
[http://dx.doi.org/10.1038/ng1161] [PMID: 12730697]
[118] Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and
protection against coronary heart disease. N Engl J Med 2006; 354(12): 1264-72.
[http://dx.doi.org/10.1056/NEJMoa054013] [PMID: 16554528]
[119] Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL
receptors in mice. J Lipid Res 2008; 49(6): 1303-11.
[http://dx.doi.org/10.1194/jlr.M800027-JLR200] [PMID: 18354138]
Lipid-Lowering Agents Frontiers in Clinical Drug Research-Diabetes & Obesity, Vol. 7 167
[120] Fonarow GC, van Hout B, Villa G, Arellano J, Lindgren P. Updated Cost-effectiveness Analysis of
Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease. JAMA Cardiol
2019; 4(7): 691-5.
[http://dx.doi.org/10.1001/jamacardio.2019.1647] [PMID: 31166576]
[121] Leaf A. Historical overview of n-3 fatty acids and coronary heart disease. Am J Clin Nutr 2008; 87(6):
1978S-80S.
[http://dx.doi.org/10.1093/ajcn/87.6.1978S] [PMID: 18541598]
[122] Singh RB. GISSI-Prevenzione trial. Lancet 1999; 354(9189): 1556-7.
[http://dx.doi.org/10.1016/S0140-6736(05)76585-5] [PMID: 10551522]
[123] Lakshmanan S, Shekar C, Kinninger A, et al. Comparison of mineral oil and non-mineral oil placebo
on coronary plaque progression by coronary computed tomography angiography. Cardiovasc Res
2020; 116(3): 479-82.
[http://dx.doi.org/10.1093/cvr/cvz329] [PMID: 31825484]
[124] Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and
other clinical studies. Eur Heart J Suppl 2020; 22 (Suppl. J): J34-48.
[http://dx.doi.org/10.1093/eurheartj/suaa117] [PMID: 33061866]
168 Frontiers in Clinical Drug Research-Diabetes & Obesity, 2023, Vol. 7, 168-207
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
CHAPTER 6
Diabesity and the Kidney
Mohamed E. Elrggal1, Ahmed Elkeraie
1,2
, Sol Carriazo3, Hany Sawaf4, Si
Yuan Khor5, Yasmine Elkeraie1, Issa Haddad5, Khaled Moustafa2 and
Mohamed Hassanein
1
Kidney and Urology Center, Alexandria, Egypt
2
Faculty of Medicine, Alexandria University, Alexandria, Egypt
3
Department of Nephrology and Hypertension, IIS-Foundation Jimenaz-Diaz-UAM, Madrid,
Spain
4
Cleveland Clinic Foundation, Cleveland, OH, United States
5
Michigan State University, East Lansing, MI, United States
6
University of Mississippi Medical Center, Jackson, MS, United States
Abstract: Diabetes Mellitus and obesity, now coined as “Diabesity”, is a worldwide
epidemic that imposes a huge burden on healthcare and society. Diabesity has been
associated with poor outcomes and increased morbidity and mortality. The kidneys are
a vulnerable target of diabesity. In this chapter, we discuss the epidemiology,
pathophysiology, and treatment of diabesity–induced kidney disease. We specifically
focus on the therapeutic targets and pharmacological management of diabesity-related
kidney diseases.
6,*
Keywords: Chronic kidney disease, Diabesity, Diabetes, Diabetic kidney disease,
Kidney failure, Obesity.
INTRODUCTION
Diabetes Mellitus (DM) and obesity, now coined as “Diabesity”, is a worldwide
epidemic that imposes a huge burden on healthcare and society [1]. Five million
deaths in 2015 were attributed to DM in people aged 20–79 years, representing
12.8% of the global all-cause mortality. In 2010, the prevalence of diabetes
worldwide was 284 million people, which represented nearly 6.4% of the whole
world population and is estimated to reach 642 million by 2040 [2, 3].
*
Corresponding author Mohamed Hassanein: University of Mississippi Medical Center 2500 North State Street,
Jackson 39216, MS, USA; Tel: +16019845670; E-mail: mhassanein@umc.edu
All rights reserved-© 2023 Bentham Science Publishers
Shazia Anjum (Ed.)
Соседние файлы в папке Библиотека им академика М.И. Перельмана